AERI News and Press, Aerie Pharmaceuticals Inc. From 08/23/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time for a breakdown of the biggest pre-market stock movers for Tuesday and the news that has them moving. Moving stocks this morning is an acquisition, a senior note of...

Alcon ( NYSE: ALC ) to acquire Aerie Pharmaceuticals ( NASDAQ: AERI ) in a deal that values Aerie at ~$770M. The purchase price of $15.25/share represents a premium of 37% to Aerie’s last closing price and represents an equity value of ~$770M. The mo...

Builds on Alcon’s existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment 1 Adds Rocklatan ® and Rhopressa ® , and a pipeline of several clinical and preclinical ophthalmic pharmaceutical produc...

Aerie Pharmaceuticals ( NASDAQ: AERI ) said one new employee was granted 16.9K stock options which will vest over four years. The company said the award was made outside of its stockholder-approved equity incentive plan and was approved by independent directors as an i...

Aerie Pharmaceuticals, Inc. (AERI) Q2 2022 Earnings Conference Call August 04, 2022 5:00 PM ET Company Participants Hans Vitzthum – Investor Relations Raj Kannan – Chief Executive Officer Peter Lang – Chief Financial Officer Gary Sternber...

Aerie Pharma ( NASDAQ: AERI ) is trading 14% higher after it reported Q2 result that beat estimates and 2022 net product revenues guidance that were in line with estimates. The company sees total glaucoma franchise net product revenues between $130M to $140M v...

Aerie Pharmaceuticals press release ( NASDAQ: AERI ): Q2 Non-GAAP EPS of -$0.32 beats by $0.23 . Revenue of $33.3M (+22.4% Y/Y) beats by $0.71M . For further details see: Aerie Pharmaceuticals Non-GAAP EPS of -$0.32 beats by $0.23, revenue of $33.3M beats...

Second Quarter Glaucoma Franchise Net Revenues of $33.3 Million, up 23% over Second Quarter 2021 Outlook for Net Cash Used Expected to Be Less Than $20 Million per Quarter, on Average, for the Remainder of 2022 Aerie Expects to be Cash Flow Break Even During 2024 ...

AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye Disease COMET-3 is the second of three studies in the AR-15512 Registrational Phase 3 Program Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a ph...

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4,...